# Exo: A Technology Company Overview
"Exo" refers to multiple distinct technology companies operating in different sectors, making a unified overview challenging. The most prominent is Exo (exo.inc), founded in 2015 and headquartered in Santa Clara, California, which specializes in portable point-of-care ultrasound (POCUS) devices and medical imaging software[1][5]. The company serves healthcare providers and clinicians by delivering handheld ultrasound machines, workflow software (Exo Works®), and AI-powered diagnostic tools that democratize medical imaging beyond traditional hospital settings[5]. With approximately $5M in revenue, Exo addresses a critical gap in healthcare accessibility—enabling immediate diagnostic imaging in remote, underserved, and resource-constrained environments[1].
The company's mission centers on "care unconstrained," envisioning a future where medical imaging is no longer bound by hospital walls[5]. By combining clinical expertise with technical innovation in material science, microelectronics, and software, Exo has positioned itself at the intersection of healthcare accessibility and technological advancement. The company's recent FDA clearance of SweepAI™—an AI system that provides real-time cardiac and lung scanning feedback without cloud dependency—demonstrates its commitment to practical, deployable solutions[5].
Exo was founded in 2015 by Sandeep Akkaraju (CEO) and Yusuf Haque, Ph.D. (CTO and EVP Engineering)[5]. The founding team assembled individuals with decades of combined experience in conquering difficult engineering challenges, drawing from backgrounds in material science, microelectronics, miniaturization, software, and data science[5]. The company emerged from a recognition that clinical experience paired with technical innovation could fundamentally reshape how medical imaging is delivered globally.
The origin reflects a deliberate strategy: rather than incremental improvements to existing ultrasound technology, the founders sought to reimagine the entire ecosystem around point-of-care imaging. This vision translated into tangible products—from portable ultrasound devices to integrated workflow software—designed with simplicity and clinical usability as core principles[5].
Exo operates within the digital health and medical device innovation sector, riding several converging trends:
Healthcare Accessibility Crisis: Global shortages of radiologists and ultrasound technicians, combined with geographic disparities in care, create urgent demand for portable, user-friendly diagnostic tools. Exo's technology directly addresses this market gap.
AI in Healthcare: The integration of machine learning into point-of-care devices reflects the broader industry shift toward AI-assisted diagnostics. Exo's offline-capable AI (no cloud dependency) addresses privacy and reliability concerns in resource-limited settings.
Miniaturization and Embedded Systems: Advances in semiconductor technology and sensor miniaturization enable sophisticated medical imaging in handheld form factors—a capability that was technically infeasible a decade ago.
Telemedicine and Remote Care: The post-pandemic acceleration of remote healthcare delivery creates natural demand for portable diagnostic equipment that extends clinical capabilities beyond traditional facilities.
Exo's influence extends beyond its direct market: by proving that enterprise-grade medical imaging can be portable and accessible, the company influences industry standards and investor expectations around healthcare technology democratization.
Exo is positioned at a critical inflection point in medical technology. The company has moved beyond prototype stage (FDA clearance of SweepAI™) and is scaling a product with clear clinical utility and market demand. Key trajectories to monitor:
Market Expansion: Adoption in underserved geographies (rural U.S., developing nations) and non-traditional settings (clinics, urgent care, field medicine) will determine revenue acceleration beyond the current $5M baseline.
AI Capability Deepening: Continued expansion of SweepAI™ to additional organ systems and diagnostic scenarios could establish Exo as the standard for AI-assisted point-of-care imaging.
Ecosystem Lock-in: Integration with electronic health records and healthcare IT infrastructure creates switching costs and recurring revenue opportunities through software subscriptions.
Competitive Pressure: Larger medical device companies (GE Healthcare, Philips, Siemens) are investing in portable ultrasound. Exo's differentiation through AI and user experience must remain ahead of well-capitalized competitors.
The company's success hinges on execution in clinical validation, regulatory expansion, and market penetration—particularly in high-impact segments like emergency medicine, obstetrics, and rural healthcare. If Exo can demonstrate measurable improvements in diagnostic accuracy and clinical outcomes while maintaining cost advantages, it could reshape how medical imaging is delivered globally.
Exo has raised $313.0M in total across 7 funding rounds.
Exo's investors include RA Capital, Action Potential Venture Capital, Energy Impact Partners, 9Yards Capital, Acrew Capital, Baseline Ventures, Catapult Capital, Crosscut Ventures, QueensBridge Venture Partners, Rashaun Williams, Tim Ferriss, Tyler Willis.
Exo has raised $313.0M across 7 funding rounds. Most recently, it raised $220.0M Series C in July 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2021 | $220.0M Series C | RA Capital | |
| Aug 1, 2020 | $40.0M Series B | Action Potential Venture Capital, Energy Impact Partners | |
| Aug 1, 2019 | $35.0M Series B | 9Yards Capital | |
| Nov 1, 2017 | $7.0M Series A | 9Yards Capital | |
| Apr 1, 2017 | $6.0M Venture Round | 9Yards Capital | |
| Apr 1, 2016 | $4.0M Series A | Acrew Capital, Baseline Ventures, Catapult Capital, Crosscut Ventures, QueensBridge Venture Partners, Rashaun Williams, Tim Ferriss, Tyler Willis | |
| Sep 1, 2014 | $1.0M Seed | Acrew Capital, Baseline Ventures, Catapult Capital, Crosscut Ventures, Rashaun Williams, Tyler Willis, Coparion, Seventure Partners |
